Brain natriuretic peptide (BNP/NPPB) is a member of the natriuretic family involved in the regulation of blood pressure and blood volume as well as lipolysis control in human fat cells. Thus BNP may play a role in energy metabolism and metabolic diseases. We therefore assessed the association between the BNP promoter T-381C polymorphism and risk of type 2 diabetes and metabolic and BNP expression traits in several population samples. In French population-based samples (n 5 3216), we found that individuals bearing the -381CC genotype had lower (P 5 0.005) fasting glucose levels than -381TC or -381TT individuals. Moreover, the -381CC genotype was less frequent in individuals with type 2 diabetes (n 5 280, 13.6%) or with impaired fasting glucose (n 5 248, 12.9%) compared with normoglycaemic individuals (n 5 2485, 17.8%). The adjusted odds ratio (OR) (95% CI) of type 2 diabetes for -381CC individuals was 0.69 (0.47 -1.00), P 5 0.05, when compared with -381T allele bearers. We replicated this association in four additional case -control studies for type 2 diabetes. The overall OR (95% CI) of type 2 diabetes was 0.85 (0.76 -0.96), P 5 0.008, (under a recessive model) (3593 cases and 6646 controls in total). We also found that the -381C allele was associated with higher plasma BNP concentrations (P 5 0.015, n 5 634) and higher BNP promoter activity in reporter gene assays. Collectively, these data suggest that relatively high BNP expression may protect against type 2 diabetes in humans.
INTRODUCTION
Brain natriuretic peptide (BNP or NPPB) is a member of the natriuretic family that also includes the atrial natriuretic peptide (ANP/NPPA) and the C-type natriuretic peptide (CNP/NPPC). BNP, although first identified in the brain, is produced mainly by the cardiac ventricules in humans. ANP and BNP biological activities are mediated by a specific receptor bearing a guanylyl cyclase activity (NPR-A), which is # The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org present in various tissues including adipose tissue (1) . BNP and ANP are involved in the regulation of blood pressure and blood volume. They exert potent natriuretic, diuretic and vasorelaxant activity (2) . However, BNP has recently been shown to be a powerful lipolytic agent in human subcutaneous fat cells via a cGMP-dependent pathway (3) . Indeed, plasma BNP concentrations are inversely correlated with body mass index (BMI) in individuals with (4) and without (5) congestive heart failure (CHF) (6) . Thus BNP may also play a role in energy metabolism and metabolic diseases, including type 2 diabetes.
In order to test this hypothesis, we looked at the genetic variability of the BNP gene in existing databases. On the NCBI dbSNP database, among the nine polymorphisms described in the genomic sequence of BNP (including 500 bp on either side of the 5 0 and 3 0 untranslated regions), seven were validated (double hit or with a known frequency) but only two were frequent enough to be explored in association studies (frequency above 5%): rs198388 and rs198389. Based on HapMap data (Rel#21/phaseII Jul06), the rs198389 polymorphism (T-381C) was a TagSNP for these two polymorphisms. Moreover, the T-381C polymorphism could be potentially functional as it was located in a regulatory region of the expression of BNP and the -381C allele disrupted a putative binding site for the AREB6 (Atp1a1 regulatory element binding factor 6) transcription factor. We therefore assessed the potential association between the T-381C polymorphism and metabolic and anthropometric quantitative traits. To complement these data we also report results from association studies between this polymorphism and risk of type 2 diabetes. Finally, we also conducted functional studies for this polymorphism.
RESULTS

Association between the T-381C polymorphism and risk of type 2 diabetes
The frequency of the -381C allele was 41% in the MONICA study (n ¼ 3216). The genotype distribution was in HardyWeinberg equilibrium (x 2 ¼ 0.63). We compared the means of BMI, waist and hip circumferences, plasma lipid, glucose, insulin levels and blood pressure values among genotype groups (Table 1) in the global sample, as it is a representative sample of the population. We found that individuals bearing the -381CC genotype had lower (P ¼ 0.005) fasting glucose levels than -381TC or -381TT individuals. No statistically significant difference could be detected among groups for the other metabolic or anthropometric variables. We then assessed the relation between the T-381C polymorphism and risk of type 2 diabetes. Consistent with the previous recessive association with fasting glucose, the -381CC genotype was less frequent in individuals with type 2 diabetes (n ¼ 280, 13.6%), compared with normoglycaemic individuals (17.8%, n ¼ 2485) ( Table 2 ). The odds ratio (OR) (95% CI) of type 2 diabetes was 0.73 (0.51 -1.04), P ¼ 0.08 for -381CC individuals. However, we only had limited statistical power to assess an association of this magnitude. As expected, a multivariate model, adjusted for age, gender, BMI, physical activity, smoking habit and center, did not materially differ from the univariate model [OR ¼ 0.69 (0.47 -1.00), P ¼ 0.05] in this recessive model. It is worth noting that the distribution of the T-381C polymorphism was also significantly different (P ¼ 0.05) between subjects with impaired fasting glucose (n ¼ 248) and control subjects (n ¼ 2485) (12.9 versus 17.8% for the -381CC genotype, respectively).
Replication of the association between the T-381C polymorphism and risk of type 2 diabetes: meta-analysis Given the suggestive evidence for statistical association in the MONICA study, we attempted to replicate the association between the BNP T-381C polymorphism and type 2 diabetes in four additional case -control studies [iNCA (iNsuffisance CAdiaque), Cambridgeshire case -control study (CCCS), EPIC (European Prospective Investigation into Cancer) and UK (United Kingdom)]. Details of genotypes by subject groups and studies are shown in Table 2 . There was no evidence of departure from Hardy -Weinberg equilibrium in control participants. Figure 1 shows that the association was consistent among studies, although only approaching statistical significance in the individual studies. For this replication study set of 3313 cases and 4161 controls, and using a fixed-effects meta-analysis, the OR (95% CI) for risk of type 2 diabetes was 0.87 (0.77 -0.98), overall P ¼ 0.027 (under a (Fig. 1 ). An association was also found in the INCA study between the -381 CC genotype and lower plasma glucose levels (0.99 + 0.28 versus 1.07 + 0.35 g/l for -381CC subjects and -381T allele bearers, respectively, P ¼ 0.05 adjusted for age, gender and BMI). As part of a sensitivity analysis, we also treated centers within the MONICA study as individual studies. We found no material difference in the magnitude of the pooled association using this approach (data not shown). A further sensitivity analysis, excluding the INCA study gave a similar pooled OR of 0.88 (0.78 -0.99), P ¼ 0.033, for men and women combined under a recessive model. This finding suggests that this study did not explain the overall pooled association.
Functional studies for the BNP T-381C polymorphism
Association between the T-381C polymorphism and plasma BNP levels. In the INCA study, the plasma mean BNP was 409 + 619 pg/ml (median: 194, range 9 -4460 pg/ml, n ¼ 208) with the fluorescence method and 263 + 344 pg/ml (median: 129, range 1 -2693 pg/ml, n ¼ 426) with the radioimmunoassay method. To increase statistical power, we combined BNP concentrations from both BNP dosage methods using 20-quantiles (see Materials and Methods section). As expected, plasma BNP levels were higher (P , 0.02) in women than in men, increased (P , 0.0001) with age, and were lower (P , 0.0001) in obese compared with non-obese individuals (Table 3) . No significant difference in plasma BNP levels could be detected between subjects with or without type 2 diabetes. We then assessed the impact of the BNP T-381C polymorphism on plasma BNP levels. We observed a trend towards higher plasma BNP levels in -381C allele bearers compared with -381TT individuals for both BNP dosage methods (Table 3) , with the homozygous CC subjects presenting the highest BNP levels. Using 20-quantiles, the -381C allele was significantly associated with higher plasma BNP levels (P ¼ 0.015) ( Table 3) . Moreover, there were more subjects carrying the -381C allele (TC þ CC subjects) than the -381TT genotype (P , 0.005) in the highest BNP quartiles compared with the lowest quartiles (Fig. 2) .
Association between the T-381C polymorphism and luciferase reporter gene assays. Finally, we evaluated the impact of the T-381C polymorphism on BNP promoter activity. We cloned the two allelic forms (-381T and -381C) of the proximal promoter (1027 bp) of BNP into the luciferase reporter pGL3-basic vector to create pGL3-BNP promoter vector. Data are n (frequency).
In COS7 cells and in the basal state, the BNP promoter displayed 1.8-fold higher activity (P ¼ 0.05) when carrying the -381C allele than when carrying the -381T allele (Fig. 3) . Because the T-381C polymorphism is located in a putative binding site for the AREB6 transcription factor (assessed using the Genomatix -Eldorado tool), we also co-transfected the pGL3-BNP vector and an expression vector encoding the human AREB6 cDNA in COS7 cells. The presence of AREB6 increased BNP promoter activity despite whatever the allele at position -381 was (1.6-and 1.7-fold for the -381T and -381C alleles, respectively, P ¼ 0.05 for both), suggesting the T-381C polymorphism did not modify AREB6 ability to enhance BNP promoter transcriptional activity (Fig. 3 ).
DISCUSSION
Consistent with recent data suggesting that BNP may be involved in energy metabolism, we observed that a functional BNP T-381C polymorphism was associated with lower plasma glucose levels and lower type 2 diabetes risk. Our data, based on 3593 cases and 6646 controls, indicate that individuals carrying the -381CC genotype may have about a 15% lower risk of type 2 diabetes compared with -381T allele carriers. This association was similar in men and women. Population stratification is unlikely to explain this association because cases are compared with the corresponding controls within study and not between studies in ethnically homogeneous populations, and controls have been taken from a similar sampling frame to relevant cases. Study estimates were also broadly similar among studies. We also found that this polymorphism had a functional influence on BNP gene expression, the -381C allele being associated with higher BNP promoter activity in reporter gene assays. Finally, we discovered that the -381C allele was associated with higher plasma BNP levels in a sample of patients with stable CHF related to left ventricular systolic dysfunction, although this result should be doublechecked in a general population-based sample, as it is known that this disease state influences BNP levels. Collectively, these data suggest that relatively higher BNP expression may protect against type 2 diabetes. BNP and ANP are natriuretic peptides recently involved in lipolysis regulation in humans, independently of the activation of the sympathetic nervous system (7). Our results confirm that plasma BNP levels are inversely correlated with BMI (4 -6). However, results on patients with type 2 diabetes are more controversial: some authors found that patients with type 2 diabetes had more circulating BNP (8) and Nt-proBNP (9) than non-diabetic individuals, whereas others found the opposite (5) or no difference at all (10) . In the INCA study, individuals with type 2 diabetes had similar plasma BNP levels than individuals without type 2 diabetes, even after adjustment for age, gender, BMI and left ventricular ejection fraction (LVEF). Because stable CHF is known to increase plasma BNP levels, this compensatory change in BNP levels may distort an association between BNP levels and risk of type 2 diabetes. Therefore, plasma BNP levels should be, in the future, measured in diabetic and normoglycaemic subjects issued from general population-based samples to clarify this point. Nevertheless, in our study, we showed that -381CC individuals had a lower risk of type 2 diabetes and higher plasma BNP levels than individuals carrying the -381T allele, suggesting that high levels of BNP could protect against type 2 diabetes. Consistent with these observations, we also found that -381CC individuals had a lower risk of impaired fasting glucose and lower fasting glucose levels in the MONICA population-based study. This association might be due to relatively higher BNP levels leading to more efficient lipolysis in fat tissue, resulting in improved insulin sensitivity. Lipolysis efficiency experiments performed in individuals with contrasted genotypes for the T-381C polymorphism might help resolve the biological basis to this association.
We also compared BNP promoter activity when carrying the -381T or -381C allele, using luciferase reporter assays in COS7 cells. We found that the BNP promoter carrying the -381C allele had a 2-fold higher activity than the BNP promoter carrying the -381T allele, independently of the AREB6 transcription factor although the -381C allele disrupts a putative binding site (NNRCACCTGKNN with the position of the T-381C polymorphism underlined) for AREB6. This suggests that AREB6 did not act via this particular putative binding site or that the presence of the -381C allele was not sufficient to alter the transactivation capability of AREB6 and that other transcriptional factors present in the cells are able to regulate BNP promoter activity in a manner depending on the allele at position -381. Other experiments are needed to determine which transcription factors are implicated in this allelespecific activity difference. There is the possibility that the BNP T-381C polymorphism might be in tight linkage disequilibrium with other nearby functional polymorphisms that could explain the present association with type 2 diabetes.
Only one other study had previously explored the impact of the BNP T-381C polymorphism on humans but not on metabolic phenotypes. Indeed, Kajita et al. showed that the T-381C polymorphism was associated with higher bonemineral density in Japanese postmenopausal women (11) . It is worth noting that the frequency of the -381C allele in Japanese was 15%, whereas it ranged from 41 to 43% in our various Caucasian samples.
In conclusion, we have shown for the first time a potential role for BNP in the etiology of type 2 diabetes in several human populations. Other studies are needed to help clarify this association.
MATERIALS AND METHODS
Study subjects
MONICA study. Participants were recruited in the framework of the WHO-MONICA population survey conducted from 1995 to 1997 in three different regions of France: the Urban Community of Lille in the north (n ¼ 1195), the Bas-Rhin county in the east (n ¼ 1131) and the Haute-Garonne county in the south (n ¼ 1182). The sample included individuals aged 35-65 randomly selected on electoral rolls after stratification by town size, gender and age to obtain 200 participants for each gender and 10-year age group (WHO-MONICA Project protocol) (12) . To our knowledge, no individuals were related. The Ethical Committee of each center approved the protocol. All participants signed an informed consent. Details of the study have been described elsewhere (13) .
From the 3216 individuals included in the French MONICA study, 280 individuals had type 2 diabetes based on a medical diagnosis and/or fasting glycaemia !7 mmol/l (1.26 g/l) and/ or on the existence of a specific treatment or diet (14) and 2485 individuals had fasting glycaemia ,6.1 mmol/l (1.10 g/l) and had no specific treatment or diet for type 2 diabetes. There were 203 individuals with unknown diabetes status and 248 individuals with intermediate fasting glucose levels (between 6.1 and 7 mmol/l).
INCA study. The INCA population consisted of 646 Caucasian consecutive ambulatory patients with stable CHF related to left ventricular systolic dysfunction (LVEF 45%) (15) . All patients had maximal tolerated doses of angiotensin converting enzyme inhibitors and beta-blockers. Patients were classified as diabetic (n ¼ 156) if they had a previous history of elevated fasting glucose (.1.26 g/l) on two separate occasions or if they were receiving oral hypoglycaemic drugs or insulin. After informed consent was obtained, blood samples were drawn in the morning at rest in fasting condition for standard biological determination, BNP determination and genetic analysis. Because the BNP dosage method changed in the hospital in 2002, plasma BNP concentrations were measured either by radioimmunoassay (Shionoria BNP kit; Shionogi & Figure 3 . Analysis of BNP promoter activity with luciferase reporter assays in COS7 cells. COS7 cells were transiently co-transfected with either empty basic-pGL3 or pGL3-BNP/-381T or pGL3-BNP/-381C promoter vector with or without AREB6 expression vector. Activity of pGL3-BNP promoter vector is expressed as fold activity compared with basic-pGL3 vector activity. White and black bars represent activities obtained for -381T and -381C alleles, respectively. Each bar represents the mean + SD of three independent experiments. Firefly luciferase activities were normalized to the renilla luciferase activities. Data were compared with the Kruskal-Wallis non-parametric test.
Ã P ¼ 0.05.
Co. Ltd, Osaka, Japan) for 426 patients (normal values were 21.1 pg/ml with inter-assay and intra-assay coefficients of variation of 4.2 and 2.7%, respectively, for the concentration of 21.1 pg/ml and 2.1 and 2%, respectively, for the concentration of 520 pg/ml) or by a fluorescence immunoassay kit (Triage, Biosite Diagnostics, San Diego, CA) for 208 patients (the average confidence limit of the analytical sensitivity is ,5 pg/ml (95% CI: 0.2 -4.8 pg/ml for a BNP range 5 -1300 pg/ml)).
Cambridgeshire case -control study. Patients aged 45 -76 with type 2 diabetes were randomly selected from general practitioner diabetes registers in Cambridgeshire, UK (16) . Criteria for type 2 diabetes were: onset of diabetes after the age of 30 years without insulin treatment in the first year of diagnosis (n ¼ 554). Controls individuals (n ¼ 532) were matched for age, sex and geographical location. Diabetes was excluded in controls by medical record search, and by an HbA1c measurement ,6%. The study received ethical approval from the Cambridge Local Research Ethics Committee and participants provided informed consent.
EPIC study. Details of the study have been described extensively previously (17) . Briefly, 353 patients had type 2 diabetes when they self-reported diabetes (physician diagnosis or dietary modification because of diabetes) and/or HbA1c .7% at the health check. Control individuals had no history of diabetes and HbA1c ,6% (n ¼ 730).
UK study. The samples examined in the UK study have all been previously described. For more details, see online appendix in (18 The individuals of the UK study were genotyped at KBiosciences (Hoddesdon, UK), using a fluorescence-based competitive allele-specific PCR system (KASPar). Assay details are available from the authors on request. Success rate was 94% with an estimated error rate of 0.87% (based on 576 duplicate pairs with complete genotypes).
Statistical analyses
Analyses were performed with the SAS statistical software release 8 (SAS Institute Inc., Cary, NC, USA). The MONICA and control samples were in Hardy -Weinberg equilibrium using the x 2 test (1 df). Pearson x 2 was used to compare genotype and allele distributions between individual groups. We calculated the association between BNP T-381C class genotype and risk of type 2 diabetes (ORs and 95% CIs) using unconditional logistical regression. In the primary analysis, we used a co-dominant genetic model, assuming a linear relationship between the number of C alleles of the BNP T-381C genetic variant. In a secondary analysis, we made a preliminary assessment of the shape of the association by visually comparing ORs under a general model. Comparison of means among genotype groups was tested with a general linear model followed by Tukey's test (comparison procedure for all pairwise groups) which led to the a posteriori use of a recessive model.
For the meta-analysis, fixed-effect summary estimates were calculated for a recessive model-based on the shape of the model found in MONICA study-as the inverse-variance weighted average of the log ORs. Heterogeneity among studies was assessed by the heterogeneity Q statistic. Meta-analyses were done using Stata version 8.2 software (Stata Corp., TX, USA).
Plasma BNP concentrations were measured using two dosage methods (see above). To combine information from both methods and to increase statistical power, BNP levels were divided into 20 quantiles for each method, and quantiles were then pooled to form a unique ordinal variable. Nonparametric tests (Mann-Whitney or Kruskal -Wallis tests when appropriate) were used to perform the analysis. The graphical representation of the influence of the BNP T-381C polymorphism on BNP levels was based on quartiles. When appropriate, covariables were age, gender, BMI and LVEF, as levels of BNP increase with the severity of the left ventricular impairment.
Data from in vitro luciferase assays were compared with the Kruskal -Wallis non-parametric test.
Cell culture COS7 cells were maintained in DMEM medium containing 10% FCS, 2 mM glutamine and 20 IU/ml penicillin/20 mg/ml streptomycin (Gibco, Invitrogen, Paisley, UK). The cells were maintained in a humidified incubator with 5% CO 2 at 378C.
Plasmids
The BNP promoter luciferase reporter vectors (pGL3-BNP) containing proximal BNP promoter (1027 bp) with either the -381T or the -381C allele were obtained from genomic DNA of individuals with known contrasted genotypes. They were generated by subcloning the PCR product amplified using the oligonucleotides: 5 0 -GAC GGT ACC CCA TCC TGT GTT GGC TTG GTG-3 0 (containing a KpnI restriction site) and 5 0 -CTG CTC GAG CTC TCT GGA GGG ACT GCG GAG-3 0 (containing a XhoI restriction site) into the KpnI and XhoI restriction sites of the basic luciferase reporter vector pGL3 (Promega, Madison, WI, USA). The insert identity was verified by sequencing and only the T-381C change was present. The expression vector (pCMV-flag2) for human AREB6 was a kind gift from Dr Kiyoshi Kawakami (Tochigi, Japan).
Transient transfections
For luciferase promoter activity assays, COS7 cells were grown to 70% confluence in 24-well plates. Transfections were carried out in serum-free DMEM with FuGENE TM transfection reagent (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions, using 300 ng luciferase reporter vector (pGL3 basic or pGL3-BNP/T or pGL3-BNP/C) with or without 300 ng AREB6 expression vector per dish. The renilla luciferase reporter vector (Promega) (20 ng) was used to normalize for transfection efficiency. Forty hours after transfection, firefly and renilla luciferase assays were performed as recommended by the manufacturer. Transfections were realized in triplicates and data of three independent experiments are presented.
